On this page
Tendon problems are common, slow to settle and frustrating enough that people try almost anything. Tendon injury and stem cell therapy has a scattered human literature — a few randomised trials in specific tendons — and one finding worth knowing: a well-conducted study where adding cells to a rotator cuff repair did not improve outcomes.
What goes wrong in a tendon
The word “tendinitis” is misleading. Chronic tendon problems are largely not inflammatory — what is found is disorganised collagen, abnormal blood vessel and nerve ingrowth, and failed healing. “Tendinopathy” is the better term.
That distinction matters practically. It is part of why anti-inflammatory approaches disappoint in chronic cases, and why repeated corticosteroid injection can weaken a tendon over time.
Tendons have poor blood supply, heal slowly, and heal with scar tissue mechanically inferior to the original.
Common sites are the Achilles, the rotator cuff at the shoulder, the common extensor origin at the elbow, and the patellar tendon. Each behaves differently under load, which is one reason evidence gathered at one site transfers poorly to another.
What actually works
Progressive loading exercise is the best-evidenced treatment in tendinopathy, and it is slow — twelve weeks minimum, often longer, with discomfort during the programme being expected rather than a sign of harm.
Eccentric and heavy slow resistance protocols both have supporting evidence. Compliance is the usual limiting factor, because the programme is dull and the results are not immediate.
That is worth naming honestly, because it explains the market. An injection is a single appointment; a loading programme is three months of unglamorous work. The injection is more appealing and the programme has the better evidence.
Load management, technique correction and addressing contributing factors elsewhere in the chain matter too. A calf that cannot take load will keep overloading an Achilles whatever is injected into it.
Any injection discussion should follow a properly completed loading programme, not replace one.
What the human trials show
A randomised controlled trial examined stem cell injection for tendon tear — A randomized controlled trial of stem cell injection for tendon tear.
Lateral epicondylosis — tennis elbow — has been studied with allogeneic adipose-derived cells — Treatment of Lateral Epicondylosis by Using Allogeneic Adipose-Derived Mesenchymal Stem Cells — and intratendinous stromal vascular fraction injection has been assessed — Intratendinous adipose-derived stromal vascular fraction (SVF) injection.
The overall clinical evidence across tendon and ligament injury has been reviewed — Mesenchymal Stem Cells for Treatment of Tendon and Ligament Injuries-clinical Evidence.
Read together, those studies describe a field at an early stage: small numbers, several different preparations, different tendons, and outcome measures that vary between studies. That is what early evidence looks like, and it is not the same as a treatment being available.
The negative result worth knowing
A randomised study found that preoperative bone marrow stimulation did not improve functional outcomes in arthroscopic rotator cuff repair — Preoperative bone marrow stimulation does not improve functional outcomes in arthroscopic cuff repair.
Negative results are rarer than they should be in this field, and this one is useful precisely because it tested a plausible idea and found it did not deliver.
A clinic citing the encouraging tendon studies without mentioning this one is presenting a selected literature.
Why the evidence is thin
Tendinopathy improves substantially with time and loading, which means any uncontrolled study will look impressive. Separating treatment from natural history requires a control group and patience.
Different tendons behave differently, so a result at the elbow does not transfer to the Achilles.
And “stem cell injection” in this literature covers several quite different things, including stromal vascular fraction, which is not a purified cell preparation at all — see MSC therapy.
Acute rupture is a different question
A complete tendon rupture — a torn Achilles, a full-thickness cuff tear with significant retraction — is a structural problem, and the decision is between surgical repair and conservative management.
Injecting cells does not reattach a ruptured tendon, and any delay while trying is a delay in a decision where timing affects the outcome.
That is a different conversation from chronic tendinopathy and should not be conflated with it. Partial tears sit somewhere between the two, and which category yours falls into is a question for imaging and examination rather than for a website.
Risks
Injection directly into a tendon is not risk-free — it can weaken the structure, and there are documented ruptures after intratendinous injection of various substances.
Infection risk applies as with any injection, and donor-site risk where cells are autologous. Injecting around rather than into the tendon is used partly to avoid the structural concern, and which of the two is being proposed is worth clarifying.
The main cost is usually opportunity: months spent on injections are months not spent on the loading programme that has the evidence — see adverse events.
A realistic position
The rationale is reasonable, the human evidence is early and mixed, and at least one well-conducted study found no benefit in a common application.
For most people with tendinopathy, a properly completed twelve-week loading programme is the intervention with the best return, and it is free. If you have not done one — not started one, completed one — that is where the next three months are best spent.
See PRP, which is cheaper, more studied in tendons, and frequently confused with cell therapy, and the research library.
Rotator cuff injury is the tendon problem with the most human evidence, including a randomised trial, and sports injuries covers the wider soft-tissue picture.
Frequently asked questions
Is tendinitis inflammation?
Usually not, once the problem is chronic. What is found instead is disorganised collagen and failed healing, which is why anti-inflammatory approaches disappoint and why repeated steroid injection can weaken the tendon.
What has the best evidence?
Progressive loading exercise, by a wide margin. It takes twelve weeks or more and compliance is the usual limiting factor.
Do the trials support cell injection?
Mixed. There are randomised trials in specific tendons, and one found that adding bone marrow stimulation to cuff repair did not improve outcomes.
Will it fix a torn tendon?
No. A complete rupture is a structural problem where the decision is surgery or conservative management, and delay affects the outcome.
Can injecting into a tendon cause harm?
It can weaken the structure, and ruptures after intratendinous injection of various substances are documented.
Does a result at the elbow apply to my Achilles?
Not reliably. Different tendons carry different loads and behave differently, and evidence does not transfer neatly between them.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.